Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Chen, Robert; Zinzani, Pier Luigi; Lee, Hun Ju; Armand, Philippe; Johnson, Nathalie A.; Brice, Pauline; Radford, John; Ribrag, Vincent; Molin, Daniël; Vassilakopoulos, Theodoros P.; Tomita, Akihiro; Tresckow, Bastian von; Shipp, Margaret A.; Lin, Jianxin; Kim, Eun‐Hee; Nahar, Akash; Balakumaran, Arun; Moskowitz, Craig H.

doi:10.1182/blood.2019000324

Cited by 287 publications

(257 citation statements)

References 5 publications

Supporting

Mentioning

231

Contrasting

Unclassified

Order By: Relevance

“…ASCT in patients with residual PET‐positive disease should not be prioritised in the setting of limited acute care services, due to poor outcomes (III) . Consider using second‐line salvage with a novel agent instead, to improve response. Options for second salvage, or transplant‐ineligible patients, include both brentuximab vedotin and pembrolizumab.The risk of respiratory complications with PD‐L1 inhibitors in the context of the COVID‐19 pandemic is unknown (III) …”

Section: Hodgkin Lymphomamentioning

confidence: 99%

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Ciaccio

McCaughan

Trotman

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

Section: Hodgkin Lymphomamentioning

confidence: 99%

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Ciaccio

McCaughan

Trotman

et al. 2020

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Blocking programmed death 1 (PD-1) signaling in relapsed Hodgkin lymphoma results in high response rates, [1][2][3] and Chen et al, in this issue of Blood, report the outcome of patients treated with pembrolizumab with 2 years of follow-up. 4 They confirm that responses in patients treated with this PD-1-blocking antibody are durable and find that patients continue to tolerate PD-1 blockade well with extended treatment.…”

mentioning

confidence: 64%

Pembrolizumab: living up to expectations

Ansell¹

2019

Blood

View full text Add to dashboard Cite

Novel treatment strategies for T-PLL are urgently needed; candidate agents in clinical development for T-PLL include anti-BCL2 (alone 9 or in combination with ibrutinib [NCT03873493]), JAK/STAT pathway inhibitors (eg, combined tofacitinib and ruxolitinib, 10 or itacitinib [NCT03989466]), and anti-histone deacetylase (eg, romidepsin [NCT02512497]). In this scenario, the availability of robust diagnostic criteria, well-established indications for treatment, and homogeneous responses represent essential tools for investigating these novel therapies. Furthermore, the systematic investigation of biological features associated with disease progression may lead to the identification of molecular targets for the development of novel therapeutic agents. Future investigations are needed to validate these criteria and to identify baseline characteristics and longitudinal indicators associated with better long-term outcomes. Hopefully, this will also lead to the identification of meaningful clinical end points that may help assess the possible impacts of novel treatments. Indeed, we need to understand whether complete remission is required for long-term survival, or if even partial remission could result in satisfactory progression-free survival, especially in the era of novel, continuously given, target therapies. In contrast, if complete remission is the initial treatment goal, we will need to understand the meaning of minimal residual disease and its role in driving therapeutic interventions for subsequent maintenance or consolidation treatments. Of course this work from the TPLL-ISG is not the end of the story, but rather a starting point that paves the way for future clinical investigations that will improve the treatment of patients with T-PLL.

show abstract

“…More recently the Bleomycin in ABVD has been supplanted by Brentuximab 9 . Newer agents such as programmed death-1 (PD-1) inhibitors such as Pembrolizumab have also been approved in the setting of relapsed and refractory classical Hodgkin's disease 10 . Meanwhile, patients with refractory disease are often salvaged and then referred for autologous stem cell transplant.…”

Section: Discussionmentioning

confidence: 99%

“Shrinking Lung” Radiation Technique in Hodgkin’s Disease

Joseph¹,

King²,

Jackson³

et al. 2020

Preprint

View full text Add to dashboard Cite

We present a case of Classical Hodgkin lymphoma, nodular sclerosis subtype, Stage IIB EX presenting with a large left lung mass, mediastinal lymph nodes, night sweats, 19% weight loss, erythrocyte sedimentation rate (ESR) of 110 ml/hr and a suboptimal response to 6 cycles of ABVD (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) chemotherapy. The patient then underwent radiation to the left lung followed by radiation to residual disease using what we describe as a “shrinking lung” radiation technique. A PET-CT done 8 months after radiation treatment was completed demonstrated a complete response. This case highlights the use of a traditional radiation technique in treatment of chemotherapy refractory Hodgkin’s lymphoma to achieve a complete remission.

show abstract

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Abstract: Chen and colleagues report excellent durability of response at 2 years for patients responding to pembrolizumab for relapsed Hodgkin lymphoma.

Cited by 287 publications

References 5 publications

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Australian and New Zealand consensus statement on the management of lymphoma, chronic lymphocytic leukaemia and myeloma during the COVID‐19 pandemic

Pembrolizumab: living up to expectations

“Shrinking Lung” Radiation Technique in Hodgkin’s Disease

Contact Info

Product

Resources

About